01—Abstract
Summary
Summary of the 8-K filed February 25, 2026. Cited figures are marked; the original filing is the authoritative source.
On February 25, 2026, Charles River Laboratories International, Inc. announced two planned divestitures.
It signed a definitive agreement to sell its contract development and manufacturing (CDMO) and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments. The businesses generated combined 2025 annual revenue of $143 milliona, including $117 million in the Manufacturing Solutions segment and $26 million in the Research Models and Services segment. The sale covers CDMO sites in Tennessee, Maryland, and the United Kingdom and a Cell Solutions site in California.
Separately, the company signed a definitive agreement to sell certain European Discovery Services assets to IQVIA Holdings Inc. for approximately $145 millionb in cash, subject to customary closing adjustments, plus potential additional payments of up to $10 million. The assets represent $144 million of 2025 annual revenue in the Discovery and Safety Assessment segment. The company will retain other drug discovery capabilities totaling approximately 40% of its 2025 Discovery Services revenue.
Both transactions are expected to close in the second quarter of 2026, subject to customary closing conditions. The company updated its 2026 guidance, first provided on February 18, 2026, to reflect the divestitures. The divestitures are expected to reduce reported revenue by slightly more than $200 millionc in 2026 and reduce organic revenue growth guidance by more than 50 basis points.
Reported revenue growth/(decrease) is now guided to (5.0)% to (3.5)%, and organic revenue growth/(decrease) to (1.5)% to (0.5)%. Non-GAAP earnings per share guidance rises to $10.80 to $11.30d from $10.70 to $11.20, reflecting approximately $0.10 of partial-year accretion. The transactions are expected to add at least 100 basis points of non-GAAP operating margin improvement in 2026.
02—Key points
Key Highlights
- Sale of CDMO and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments; the businesses generated $143 million of combined 2025 revenue.
- Sale of certain European Discovery Services assets to IQVIA Holdings Inc. for approximately $145 million in cash, plus potential additional payments of up to $10 million, covering $144 million of 2025 revenue.
- Both transactions are expected to close in the second quarter of 2026, subject to customary closing conditions.
- 2026 reported revenue growth/(decrease) guidance is now (5.0)% to (3.5)%, including an impact of approximately (5.0)% from the divestitures.
- Organic revenue growth/(decrease) guidance is now (1.5)% to (0.5)%, reflecting an organic impact of more than (0.5)% from the divestitures.
- Non-GAAP EPS guidance is raised to $10.80 to $11.30 from $10.70 to $11.20, including approximately $0.10 of partial-year accretion.
- The transactions are expected to generate at least 100 basis points of incremental non-GAAP operating margin improvement in 2026. Divestiture-related costs have not been finalized.
03—Questions
Frequently Asked Questions
What businesses is Charles River Laboratories selling?
The company is selling its CDMO and Cell Solutions businesses to GI Partners, including CDMO sites in Tennessee, Maryland, and the United Kingdom and a Cell Solutions site in California. It is also selling certain European Discovery Services assets to IQVIA Holdings Inc., including a Cambridge, UK site and pharmacology sites in Freiburg, Germany; Kuopio, Finland; Portishead, UK; and Leiden, Netherlands.
How much cash will the company receive from the divestitures?
The European Discovery Services sale to IQVIA is for approximately $145 million in cash, subject to customary closing adjustments, plus potential additional payments of up to $10 million. The CDMO and Cell Solutions sale to GI Partners is primarily for future, contingent performance-based payments, and the filing does not state a fixed purchase price for it.
How will the divestitures affect 2026 guidance?
The divestitures are expected to reduce reported revenue by slightly more than $200 million in 2026 and reduce organic revenue growth guidance by more than 50 basis points. Non-GAAP EPS guidance is updated to $10.80 to $11.30, which includes approximately $0.10 of partial-year accretion. The updated guidance assumes both transactions close in the second quarter of 2026.
What costs are excluded from the non-GAAP earnings guidance?
Excluded items are expected to include divestiture-related costs, which primarily consist of transaction, advisory, and certain transition costs. The company has not finalized these estimates, and it did not provide a GAAP reconciliation for the guidance.
What remains in the Discovery Services business after the sale?
The company will retain other drug discovery capabilities totaling approximately 40% of its Discovery Services revenue in 2025. The company also states that it will continue to assess the potential value of reporting non-GAAP results.
04—Continue